Sector News

Cost-cutting, check. Now, it’s on to dealmaking, Teva chief says

February 6, 2015
Life sciences
Okay, pharma. Teva is ready to make some deals now. Really. It’s serious.
 
It’s a mantra that’s seen quite a bit of play since CEO Erez Vigodman took up the reins at the generics giant early last year. But now, after a year of focusing on cutting costs and debt, and turning things around at the struggling drugmaker, he really means it.
 
“In 2015 we are reorienting towards inorganic moves,” he said on the company’s fourth-quarter conference call, as quoted by Reuters. Translation: We’re shopping.
 
As he’s said before, Vigodman has his eye on emerging markets and complex generics, to name a couple of potential deal targets. Rumors about a Mylan merger have persisted, though plenty of analysts have their doubts about that one. Perrigo, the OTC-focused drugmaker now based in Ireland, or Sweden’s Meda could also make sense, industry watchers have suggested.
 
So far, Teva itself has been quiet on the acquisition front, despite the wave of deals that took pharma by storm in 2014. “Teva has a healthy business, but in this environment if you’re not doing deals, you’re probably not taking advantage of the opportunities that are out there,” Gabelli & Co. analyst Kevin Kedra told Bloomberg last month.
 
Whatever M&A moves Teva does ultimately make could help the company on its quest to return to growth–especially if they’re in the generics department. Last quarter, generics revenue fell 8% to $2.47 billion, propelling a 4.8% overall sales drop. The decline was in line with analyst expectations, Bloomberg said.
 
Teva’s generics sales also took a dip on the full year, despite contributions from knockoffs of AbbVie’s heart pill Niaspan and Merck’s  brain cancer drug Temodar.
 
By Carly Helfand
 

comments closed

Related News

July 3, 2022

Novo Nordisk joins with nursing group to highlight correlation between Type 2 diabetes and cardio risk

Life sciences

Despite atherosclerotic cardiovascular disease (ASCVD) being the leading cause of death for people with Type 2 diabetes, half of those people have no idea of this risk. Novo Nordisk has teamed up with the Preventive Cardiovascular Nurses Association (PCNA) for “Making the Connection,” a program to help increase understanding of the link between the two diseases.

July 3, 2022

First treatment for ‘broken heart syndrome’ trialled

Life sciences

The first ever treatment for broken heart syndrome – also known as Takotsubo cardiomyopathy – is to be trialled by researchers at the University of Aberdeen. Scientists will trial a programme of exercise conditioning and psychological therapy for people who have been diagnosed with the condition following a £300,000 grant from the British Heart Foundation.

July 3, 2022

Nestlé acquiring The Better Health Company in market expansion deal

Life sciences

Nestlé Health Science is set to acquire The Better Health Company (TBHC), as part of its goals to grow global market share while spurring innovation across the nutrition industry. The acquisition includes the GO Healthy brand with its vitamins and supplements, Egmont, the Manuka honey brand and New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins minerals and supplements.